Vikram Sudarsan
CEO
Engrail Therapeutics
Engrail Therapeutics develops precision-targeted therapeutics for patients with life-limiting neurological disorders by leveraging expertise in molecular mechanisms and neurocircuitry. The company aims to provide effective treatments that address the unmet medical needs of individuals suffering from these debilitating conditions.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$157MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many neurological disorders lack effective treatments, leaving patients with life-limiting conditions and unmet medical needs. The complexity of the nervous system and the intricate molecular mechanisms underlying these disorders pose significant challenges to developing targeted therapeutics.
Solution
Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing precision-targeted therapeutics for neurological disorders. By leveraging expertise in molecular mechanisms and neurocircuitry, Engrail aims to create innovative treatments that address the underlying causes of these debilitating conditions. The company's pipeline is built through strong partnerships and internal discovery capabilities, with a commitment to rapidly advancing its therapeutic candidates through clinical development.
Target Audience
The primary target audience includes patients suffering from life-limiting neurological disorders and the healthcare professionals who treat them.
Features
- Focus on precision neuroscience to target specific molecular mechanisms and neurocircuitry
- Innovative pipeline of therapeutic candidates for various neurological disorders
- Commitment to advancing therapeutics through clinical development
- Pipeline includes ENX-102, ENX-104, ENX-203, and ENX-205
- Built through strong partnerships and internal discovery capabilities